person · Reporting owner

CHYUNG YUNG H.

Disclosed activity across 3 companies

Tapewire entity: 83031
SEC CIK: 0001740377

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Keros Therapeutics, Inc.KROS · Entity 6242	Chief Medical Officer	February 18, 2025	February 19, 2025
Scholar Rock Holding CorpSRRK · Entity 3721	Chief Medical Officer	February 14, 2022	February 15, 2022
Tourmaline Bio, Inc.TRML · Entity 15643	Chief Medical Officer	October 19, 2023	October 23, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Keros Therapeutics, Inc.

Report date February 18, 2025 · Filed February 19, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	44,000	Reported balance After 2025-02-18 transaction · row 1 1 source row Row 1 · 2025-02-18 · Grant · Acquired 44,000 · Balance 44,000 F1: Represents a restricted stock unit ("RSU") award. The RSUs vest as follows: 33% of the RSUs shall vest on February 17, 2026, an additional 34% of the total number of RSUs shall vest on August 15, 2026, and the remaining 33% of the total number of RSUs shall vest on February 16, 2027, in each case, subject to the Reporting Person's Continuous Service (as defined in the 2020 Plan) through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit ("RSU") award. The RSUs vest as follows: 33% of the RSUs shall vest on February 17, 2026, an additional 34% of the total number of RSUs shall vest on August 15, 2026, and the remaining 33% of the total number of RSUs shall vest on February 16, 2027, in each case, subject to the Reporting Person's Continuous Service (as defined in the 2020 Plan) through each applicable vesting date.

Scholar Rock Holding Corp

Report date February 14, 2022 · Filed February 15, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	258,496	Reported balance After 2022-02-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-02-14 · Grant · Acquired 37,500 · Balance 258,496 F1: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on January 15, 2023 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Company on such vesting date. F2: Consists of 209,183 shares of common stock and 49,313 RSUs.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.08 · Expires 2032-02-14	Direct	37,500	Reported balance After 2022-02-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-02-14 · Grant · Acquired 37,500 · Balance 37,500 F3: Options vest and become exercisable in sixteen quarterly installments over four years. Vesting commenced on January 1, 2022 and the first vesting event shall occur three months thereafter; provided the reporting person continues to have a service relationship with the Company on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on January 15, 2023 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Company on such vesting date.

F2: Consists of 209,183 shares of common stock and 49,313 RSUs.

F3: Options vest and become exercisable in sixteen quarterly installments over four years. Vesting commenced on January 1, 2022 and the first vesting event shall occur three months thereafter; provided the reporting person continues to have a service relationship with the Company on such vesting date.

Tourmaline Bio, Inc.

Report date October 19, 2023 · Filed October 23, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	56,836	Reported balance After 2023-10-19 transaction · row 1 1 source row Row 1 · 2023-10-19 · Grant · Acquired 56,836 · Balance 56,836 F1: 41,443 of these shares are subject to a repurchase option in favor of the Issuer in the event that the Reporting Person's continuous service is terminated. Such repurchase option shall lapse in equal monthly installments until such shares are fully vested on June 1, 2026. F2: Received in exchange for 712,500 shares of common stock of Tourmaline Bio, Inc. ("Tourmaline") pursuant to an Agreement and Plan of Merger dated as of June 22, 2023 (the "Merger Agreement") by and among Tourmaline, the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on October 19, 2023, Merger Sub merged with and into Tourmaline (the "Merger"), with Tourmaline surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Tourmaline common stock was converted into the right to receive 0.07977 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 10-for-1. Subsequent to the Merger, the name of the Issuer was changed from Talaris Therapeutics, Inc. to Tourmaline Bio, Inc.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.90 · Expires 2033-06-17	Direct	144,215	Reported balance After 2023-10-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-10-19 · Grant · Acquired 144,215 · Balance 144,215 F3: Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F5: Received in exchange for a stock option to acquire 1,807,900 shares of Tourmaline common stock pursuant to the Merger Agreement. F4: The shares subject to the option vest as to 25% of the shares on June 14, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.46 · Expires 2033-10-22	Direct	73,211	Reported balance After 2023-10-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-10-23 · Grant · Acquired 73,211 · Balance 73,211 F6: The shares subject to the option vest as to 25% of the shares on October 23, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 41,443 of these shares are subject to a repurchase option in favor of the Issuer in the event that the Reporting Person's continuous service is terminated. Such repurchase option shall lapse in equal monthly installments until such shares are fully vested on June 1, 2026.

F2: Received in exchange for 712,500 shares of common stock of Tourmaline Bio, Inc. ("Tourmaline") pursuant to an Agreement and Plan of Merger dated as of June 22, 2023 (the "Merger Agreement") by and among Tourmaline, the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on October 19, 2023, Merger Sub merged with and into Tourmaline (the "Merger"), with Tourmaline surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Tourmaline common stock was converted into the right to receive 0.07977 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 10-for-1. Subsequent to the Merger, the name of the Issuer was changed from Talaris Therapeutics, Inc. to Tourmaline Bio, Inc.

F3: Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split.

F4: The shares subject to the option vest as to 25% of the shares on June 14, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.

F5: Received in exchange for a stock option to acquire 1,807,900 shares of Tourmaline common stock pursuant to the Merger Agreement.

F6: The shares subject to the option vest as to 25% of the shares on October 23, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 18, 2025 Filed Feb 19, 2025 21:15 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	GrantCommon Stock	44,000	$0.00	$0.00	Disclosure SEC source: 0001415889-25-004598 · form4-02192025_040212.xml · nonDerivative · entry 1 CHYUNG YUNG H. · CIK 0001740377 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs vest as follows: 33% of the RSUs shall vest on February 17, 2026, an additional 34% of the total number of RSUs shall vest on August 15, 2026, and the remaining 33% of the total number of RSUs shall vest on February 16, 2027, in each case, subject to the Reporting Person's Continuous Service (as defined in the 2020 Plan) through each applicable vesting date. Read SEC document
November 08, 2024 Filed Nov 12, 2024 21:15 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	GrantEmployee Stock Option (right to buy) · Derivative	110,000	$0.00 Strike: $67.91	$0.00	Disclosure SEC source: 0001415889-24-026598 · form4-11122024_041110.xml · derivative · entry 1 CHYUNG YUNG H. · CIK 0001740377 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2034-11-07 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on November 1, 2025, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
October 23, 2023 Filed Oct 23, 2023 20:20 UTC	Tourmaline Bio, Inc. TRML · Entity 15643	GrantEmployee Stock Option (Right to Buy) · Derivative	73,211	$0.00 Strike: $9.46	$0.00	Disclosure SEC source: 0001209191-23-053391 · doc4.xml · derivative · entry 3 CHYUNG YUNG H. · CIK 0001740377 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,211 Underlying: Common Stock · 73,211 shares Expires 2033-10-22 F6 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on October 23, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
October 19, 2023 Filed Oct 23, 2023 20:20 UTC	Tourmaline Bio, Inc. TRML · Entity 15643	GrantEmployee Stock Option (Right to Buy) · Derivative	144,215	Not disclosed Strike: $7.90	Not disclosed	Disclosure SEC source: 0001209191-23-053391 · doc4.xml · derivative · entry 2 CHYUNG YUNG H. · CIK 0001740377 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,215 Underlying: Common Stock · 144,215 shares Expires 2033-06-17 F3 · derivative.exercise_price: Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F3 · shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F3 · price: Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F5 · price: Received in exchange for a stock option to acquire 1,807,900 shares of Tourmaline common stock pursuant to the Merger Agreement. F4 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on June 14, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. F3 · derivative.underlying_shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. Read SEC document
October 19, 2023 Filed Oct 23, 2023 20:20 UTC	Tourmaline Bio, Inc. TRML · Entity 15643	GrantCommon Stock	56,836	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-053391 · doc4.xml · nonDerivative · entry 1 CHYUNG YUNG H. · CIK 0001740377 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,836 F1 · shares: 41,443 of these shares are subject to a repurchase option in favor of the Issuer in the event that the Reporting Person's continuous service is terminated. Such repurchase option shall lapse in equal monthly installments until such shares are fully vested on June 1, 2026. F2 · price: Received in exchange for 712,500 shares of common stock of Tourmaline Bio, Inc. ("Tourmaline") pursuant to an Agreement and Plan of Merger dated as of June 22, 2023 (the "Merger Agreement") by and among Tourmaline, the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on October 19, 2023, Merger Sub merged with and into Tourmaline (the "Merger"), with Tourmaline surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Tourmaline common stock was converted into the right to receive 0.07977 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 10-for-1. Subsequent to the Merger, the name of the Issuer was changed from Talaris Therapeutics, Inc. to Tourmaline Bio, Inc. Read SEC document
February 14, 2022 Filed Feb 15, 2022 22:15 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantStock Option (Right to Buy) · Derivative	37,500	$0.00 Strike: $18.08	$0.00	Disclosure SEC source: 0001104659-22-023861 · tm226853-1_4seq1.xml · derivative · entry 2 CHYUNG YUNG H. · CIK 0001740377 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2032-02-14 F3 · derivative.exercise_date: Options vest and become exercisable in sixteen quarterly installments over four years. Vesting commenced on January 1, 2022 and the first vesting event shall occur three months thereafter; provided the reporting person continues to have a service relationship with the Company on such vesting date. Read SEC document
February 14, 2022 Filed Feb 15, 2022 22:15 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantCommon Stock	37,500	$0.00	$0.00	Disclosure SEC source: 0001104659-22-023861 · tm226853-1_4seq1.xml · nonDerivative · entry 1 CHYUNG YUNG H. · CIK 0001740377 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,496 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on January 15, 2023 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Company on such vesting date. F2 · balance_after: Consists of 209,183 shares of common stock and 49,313 RSUs. Read SEC document
January 18, 2022 Filed Jan 20, 2022 00:01 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	Tax withholdingCommon Stock	1,421	$19.46	$27,656.92	Disclosure SEC source: 0001104659-22-005566 · tm223899-2_4seq1.xml · nonDerivative · entry 1 CHYUNG YUNG H. · CIK 0001740377 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,996 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSU") on January 15, 2022. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to an award that was granted on February 1, 2021. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU award vest annually over four years, subject to a continued service relationship with the Issuer on such vesting date. F2 · price: The price reported above represents the weighted average selling price, as the transaction was executed in multiple trades. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected to the SEC staff upon request. F3 · balance_after: Consists of 209,183 shares of common stock and 11,813 RSUs. Read SEC document
February 01, 2021 Filed Feb 3, 2021 22:10 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantStock Option (Right to Buy) · Derivative	52,500	$0.00 Strike: $58.93	$0.00	Disclosure SEC source: 0001179110-21-001253 · edgar.xml · derivative · entry 2 CHYUNG YUNG H. · CIK 0001740377 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,534 Underlying: Common Stock · 52,500 shares Expires 2031-02-01 F2 · derivative.exercise_date: Shares will vest and become exercisable quarterly over four years, subject to a continued service relationship with the Issuer on such vesting date. Read SEC document
February 01, 2021 Filed Feb 3, 2021 22:10 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantCommon Stock	15,750	$0.00	$0.00	Disclosure SEC source: 0001179110-21-001253 · edgar.xml · nonDerivative · entry 1 CHYUNG YUNG H. · CIK 0001740377 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU award will vest and become exercisable quarterly over four years, subject to a continued service relationship with the Issuer on such vesting date. Read SEC document
February 06, 2020 Filed Feb 10, 2020 22:22 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantStock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $13.52	$0.00	Disclosure SEC source: 0001179110-20-001383 · edgar.xml · derivative · entry 1 CHYUNG YUNG H. · CIK 0001740377 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2024-01-01 F1 · derivative.exercise_date: Shares will vest and become exercisable quarterly over four years, with the first vesting event on April 1, 2020; subject to a continued service relationship with the company on each such vesting date. Read SEC document
January 31, 2019 Filed Feb 5, 2019 00:37 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantStock Option (Right to Buy) · Derivative	56,000	$0.00 Strike: $15.11	$0.00	Disclosure SEC source: 0001104659-19-005624 · a4.xml · derivative · entry 1 CHYUNG YUNG H. · CIK 0001740377 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2029-01-31 F1 · derivative.exercise_date: This option vests quarterly over four (4) years, with the first quarterly amount vesting on March 31, 2019. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.